Aspirin eugenol ester regulates cecal contents metabolomic profile and microbiota in an animal model of hyperlipidemia

Table 3 Potential biomarkers in cecal contents based on the UPLC-Q-TOF/MS analysis and the changes between different groups

SM	RT	VIP	Metabolite	Formula	m/z	Adduction	Fold change		Pathway
SM	RT	VIP	Metabolite	Formula	m/z	Adduction	M/C	AEE/M	Pathway
+	2.26	2.92	Hypoxanthine	C₅H₄N₄O	137.0459	[M + H]⁺	0.39^**	1.12	Purine metabolism
+	18.11	2.04	Linoleic acid	C₁₈H₃₂O₂	281.2479	[M + H]+	3.78^**	0.81	Linoleic acid metabolism
+	17.84	1.40	LysoPC(18:1(9Z))	C₂₆H₅₂NO₇P	522.3606	[M + H]+	1.90^*	0.47^*	Glycerophospholipid metabolism
+	19.32	1.01	Linoleoyl ethanolamide	C₂₀H₃₇NO₂	324.2905	[M + H]+	1.59^*	0.88	–
+	21.26	2.51	Oleamide	C₁₈H₃₅NO	282.2796	[M + H]+	2.19^*	0.49^*	–
+	14.81	8.12	Sphingosine	C₁₈H₃₇NO₂	300.2904	[M + H]+	2.98^**	0.52^**	Sphingolipid metabolism
–	2.99	1.07	Uridine	C₉H₁₂N₂O₆	243.0622	[M-H]-	0.35^**	1.14	Pyrimidine metabolism
–	10.40	1.17	Sebacic acid	C₁₀H₁₈O₄	201.1132	[M-H]-	0.49^*	1.43	–

SM scan model, RT retention time, VIP Variance importance for projection, LysoPC, Lysophosphatidylcholine, M/C: model versus control, AEE/M: AEE versus model, ^*P < 0.05, ^**P < 0.01 compared with corresponding group

ISSN: 1746-6148